rin NSAIDs reversibly inhibit cyclooxygenase (COX) enzymes 1 and 2, preventing the conversion of arachidonic acid to proinflammatory prostaglandins, thus producing antipyretic and analgesic effects. COX enzymes are ubiquitous; therefore, NSAID administration also predisposes a number of tissues to undesired side effects. NSAID administration can result in unwanted effects in the kidneys, the gastric and intestinal mucosa, and platelets, among other tissues. NSAIDs alter platelet function by inhibiting the synthesis of procoagulant thomboxanes, which are stored in platelet granules. Inhibition of COX by NSAIDs has been shown to alter platelet function and prolong bleeding times in healthy volunteers, 5, 14, 15, 24 though bleeding times generally remain within normal limits. 14 The prolongation of bleeding times and platelet function has led to numerous clinical studies that have investigated the safety of NSAID administration in postoperative patients. Some clinical safety studies have demonstrated that administration of NSAIDs leads to an increase in postoperative bleeding events, 3, 9, 10, 19, 20 whereas other studies have demonstrated the NSAIDs can be safely administered postoperatively. 11, 13, 14, 17, 18, 23, 25, 26, 28 Since 2000, we have routinely used ketorolac as a component of the perioperative analgesic regimen during the first 72 hours following pediatric neurosurgical procedures. We sought to assess whether this strategy was associated with an increased risk for hemorrhagic or systemic complications.
methods study design and sample
Following approval by the Colorado Multiple Institutional Review Board, we retrospectively reviewed 2657 consecutive neurosurgery procedures that had adequate electronic data. Procedures were performed in 1593 patients at Children's Hospital Colorado between December 2006 and April 2012. Data were collected from electronic health records by 2 trained research assistants and a neurosurgery resident (M.R.). Ten percent of records were double entered independently to verify consistency. Discrepancies were resolved by the senior author.
Surgical procedures were stratified based on an estimation of hemorrhagic complications by the 2 senior authors (M.H.H. and T.C.H.) ( Table 1 ). The 5 categories, in order of a priori perceived risk, were 1) craniotomy/craniectomy with dural opening (except for Chiari malformation Type I ); 2) intradural placement of a catheter or endoscope; 3) craniotomy/craniectomy without dural opening plus procedures for Chiari malformation Type I); 4) spinal procedures; and 5) minor procedures (e.g., external ventricular drain [EVD], intracranial pressure monitor, or vagus nerve stimulator placement). Chiari malformation decompression with dural opening was included in the third category because our institutional practice is to perform minimal intradural maneuvers during these procedures. Placement of EVDs was considered a minor procedure and included in Category 5 because of the shorter duration of the procedure and decreased tissue manipulation (shunt passage and intraperitoneal exposure) compared with a shunt procedure. For each patient, a single surgical procedure type (Type 1-5), termed the "index procedure," was identified ( Table 1) . For patients who underwent multiple operations, the procedure in the highest risk category (Table 1) was assessed, and all other procedures were excluded from analysis. In the case of multiple procedures within the highest risk category for a given patient, the first procedure chronologically was analyzed. The single exception to this was planned 2-stage craniotomy for intradural electrode monitoring followed by resection of epileptogenic tissue. In these cases, the second-stage procedure was assessed, based on the a priori belief that a resective procedure is associated with greater risk for hemorrhage than grid or electrode placement.
From the 1593 index procedures assessed, those associated with an elevated risk of harboring hemorrhage preoperatively were excluded. These included 1) patients with procedures that occurred within 7 days of presentation following trauma (n = 59) and 2) patients with radiographically documented intracranial or intraspinal hemorrhage within 7 days prior to surgery (n = 114). Thirty-one cases had both exclusion criteria. The remaining 1451 procedures composed the study sample.
covariables
In addition to reviewing the surgical procedures, we assembled a list of medications that are associated with increased risk for hemorrhage and termed them "pharmacological confounders." This list included systemic-dose anticoagulants (not low-dose prophylactic heparins), antiplatelet agents, valproic acid, and NSAIDS other than ketorolac. Due to ubiquitous inpatient use and undocumented outpatient use, ibuprofen was not considered a pharmacological confounder. While there is debate as to whether valproic acid is associated with an increased likelihood of hemorrhage, 2, 6, 7, 29 our clinical practice has been to treat it as such. If at least 1 dose of the medication was administered during the 24 hours prior or 72 hours following the index procedure, the patient was considered to have had a pharmacological confounder. Age, sex, surgical procedure, surgeon, and craniotomy for epilepsy were also examined as covariables.
exposure
Exposure was defined as the administration of at least 1 dose of ketorolac during the 24 hours prior to or 72 hours following the index procedure.
outcomes
Outcome measures included clinically significant postoperative bleeding, radiographically identified postopera- tive hemorrhage, and newly incident renal failure and/or gastrointestinal ulcer or hemorrhage.
Clinically significant bleeding events were defined as postoperative hemorrhages that required a return to the operating room for evacuation of a hematoma. Radiographically identified hemorrhage was assessed on axial imaging (CT scan or MRI) performed within 7 days of the index procedure. The presence of hemorrhage was identified from the impression section of the pediatric neuroradiologist's final report. Postoperative hemorrhage described as "thin," "minor," "mild," or "small" was not considered a positive finding. Any other description was considered positive and preliminarily labeled as bleeding on imaging. To confirm the findings, all scans noted in the radiology interpretation to harbor hemorrhage (however small) were reviewed by the senior author, who was blinded to whether the subject had received ketorolac.
Renal failure was defined as a doubling of the preoperative serum creatinine value. If all postoperative values were within the normal range in the absence of a preoperative value, then the patient was considered to not have renal failure. If no postoperative value was available, then the outcome could not be assessed. Only 648 patients received postoperative laboratory analysis of creatinine level as a measure of renal function. The development of gastrointestinal insult was identified through analysis of clinical documentation. This included evaluation for ICD-9-CM diagnosis Codes 531-534 (ulcers in the gastric, duodenal, gastrojejunal and unspecified regions) and 578 (gastrointestinal hemorrhage) and correlation of these with notes from appropriate specialty services, including critical care, pediatrics, and gastroenterology. For the assessment of both renal failure and gastrointestinal tract injury, records were reviewed from the 30 days following the surgical procedure or the entirety of the relevant admission, whichever was longer. Records were also assessed to evaluate whether these conditions existed in the patients prior to the index procedure and were not considered a complication if found to be preexisting.
statistical analyses
Descriptive statistics were examined. Bivariable analyses were performed to assess the relationship between covariables and the exposure, as well as covariables and the outcomes, to evaluate potential confounding variables. Chi-square, Fisher exact, and Wilcoxon rank-sum tests were performed. Variables that were associated with both the exposure and clinical bleeding event (p < 0.20) were evaluated as potential confounders for that relationship. Multivariable logistic regression was performed and adjusted ORs and 95% CIs were estimated. Craniotomy for epilepsy and brain resection and the surgeon were colinear, so we only omitted surgeon from the multivariable model. Six surgeons performed procedures during the study period (Table 2 ). For purposes of uniformity of case numbers in analysis, surgeons were combined into 3 surgical groups (Tables 3 and 4 ). Craniotomy for epilepsy was evaluated as a possible effect modifier. The multivariable model for the association between ketorolac and radiographic bleeding included the presence of a pharmaceutical confounder, the surgical procedure (dichotomized), craniotomy for epilepsy and brain resection, and the use of ketorolac. A crude odds ratio and 95% CI were estimated to evaluate the relationship between ketorolac and clinically significant bleeding events, because the number of bleeding events was small (n = 7).
Statistical analyses were performed with SAS 9.3 (SAS Institute).
results study sample
A total of 1451 index procedures were identified. The median age at surgery was 4.8 years (range 0-30 years), with 453 (31.2%) procedures performed in patients less than 1 year old and 462 (31.8%) in patients 10 or more years old. Ketorolac was administered in 955 cases (65.8%). Axial imaging was performed within 7 days following the index procedure in 539 cases (37.15%) ( Table 2) .
Two patients (0.1%) developed gastrointestinal tract ulceration and 2 of 648 (0.3%) suffered from documented renal failure. All of these patients received ketorolac, but the incidence of these events was too small to allow for statistical analysis. The 2 cases of documented renal failure were not specifically attributable to ketorolac administration, as 1 patient suffered from concurrent urinary retention and received another potentially nephrotoxic agent (vancomycin) and the other patient did not have a preke- torolac serum creatinine level measured for comparison (though serum creatinine levels after ketorolac administration indicated a decreased glomerular filtration rate). Seven patients experienced clinically significant bleeding events and are detailed as follows. Patient 1, an 18-yearold girl, developed progressive upper-extremity weakness following a complex decompression of a Chiari malformation. Imaging revealed a postoperative hematoma that required surgical evacuation. Patient 2 was a 15-year-old boy in whom a postoperative hematoma surrounding the pulse generator developed after vagus nerve stimulator placement. Patient 3, a 12-year-old boy, suffered an intraventricular hemorrhage following ventriculoperitoneal shunt placement. The hemorrhage, surrounding the proximal tip of the catheter, resulted in proximal shunt failure and emergency revision because of declining function on neurological examination. Patient 4 was a 14-year-old girl who underwent an encephaloduroarteriosynangiosis and developed a postoperative hematoma at the operative site that required evacuation. Of note, she was receiving a bridging anticoagulation regimen (low-molecular-weight heparin to oral anticoagulation) at the time of the event. Patient 5, a 14-year-old boy, underwent evacuation of a subdural empyema and developed a subdural hematoma and recurrent empyema that required surgical evacuation 4 days following the initial surgery. Patient 6 was a 4-year-old boy who had undergone recent heart transplantation and was taking warfarin (Coumadin; Bristol-Myers Squibb Co.). He developed a spontaneous left frontal hematoma, sub-arachnoid hemorrhage, and an acute-on-chronic subdural hematoma. Two days following the initial neurosurgery, he developed a recurrent subdural hematoma that required emergency evacuation. Patient 7, a 20-year-old man who underwent subdural grid implantation and developed aphasia following the procedure, was found to have a modest subdural hematoma that required evacuation.
Ketorolac administration
Bivariable analysis (Table 3 ) demonstrated no difference in ketorolac administration based on patient age or sex. Patients who received a medication that might have increased perioperative bleeding risk were less likely to receive ketorolac (46.7% vs 66.4%; p = 0.006). Patients who underwent a minor procedure (e.g., EVD or intracranial pressure monitor placement) and those who underwent a procedure that involved intradural catheter placement (e.g., ventricular shunt or endoscopy) were less likely to receive ketorolac than patients who underwent other procedures (overall p < 0.0001). Among patients who underwent neurosurgical procedures, ketorolac administration rates were as follows: Group 1 (craniotomy/craniectomy with dural opening [except for Chiari malformation Type I]), 75.6%; Group 2 (intradural placement of a catheter or endoscope), 32.5%; Group 3 (craniotomy/craniectomy without dural opening plus procedures for Chiari malformation Type I), 83.2%; Group 4, 93.8%; and Group 5 (minor procedures), 31.0%. bleeding A total of 7 clinically significant bleeding events were identified (0.5%) ( Table 4 ). There was no statistically significant difference, according to bivariable analysis, between patients who did or did not receive ketorolac and the development of a significant bleeding event (p = 0.70). Among those in whom ketorolac was used (n = 955), there were 4 bleeding events (0.42%), and there were 3 events among the 496 patients who did not receive ketorolac (0.60%). Among the parameters assessed, the presence of a pharmaceutical confounder and older age were associated with an elevated risk of a significant bleeding event (p = 0.018 and 0.007, respectively) ( Table 4) .
A total of 539 patients (37.15%) had axial imaging within 7 days following the index procedure (Table 5 ). Among these, there were 56 studies (10.4%) that demonstrated postoperative hemorrhage. There was no statistically significant difference between patients who did or did not receive ketorolac and the presence of postoperative hemorrhage on imaging (p = 0.48). Craniotomy for epilepsy did not act as an effect modifier for the relationship be-tween ketorolac and postoperative hemorrhage on imaging (p = 0.93). Among those in whom ketorolac was used (n = 313), there were 35 positive imaging studies (11.1%), whereas there were 21 positive studies among the 226 patients who did not receive ketorolac (9.3%). The presence of a pharmaceutical confounder was associated with an elevated likelihood of identifying hemorrhage on the postoperative imaging study (p = 0.038). Craniotomy for epilepsy and brain resection was associated with bleeding on imaging, as was the surgeon (Table 5 ). Following craniotomy/craniectomy, regardless of whether the dura was opened, 10.5%-13.9% of patients (Categories 1 and 3) had positive findings on postoperative imaging. Among other procedure categories, positive findings were identified in 0.0%-6% of patients. For the multivariable analysis, surgical procedure, therefore, was dichotomized into craniotomy/craniectomy or other.
multivariable analyses
Bivariable analysis indicated that age and pharmaceutical confounder might confound the relationship between ketorolac and clinically significant postoperative hemorrhage. Because of the small number of events (n = 7), we were not able to assess this. However, in bivariable analysis, ketorolac was not associated with an elevated likelihood of clinically significant bleeding events (OR 0.69; 95% CI 0.15-3.10). The model fit was not optimal (c = 0.544).
In assessing the risk of a radiographically identified postoperative hemorrhage, the presence of a pharmaceutical confounder, the category of surgical procedure, the surgeon, and undergoing craniotomy for epilepsy reached the threshold of p < 0.20 for both the bivariable exposure and outcome relationships (Tables 2 and 4). As described, the category of surgical procedure was dichotomized and the surgeon, as a variable, was omitted due to collinearity with surgical procedure. The multivariable model, therefore, included ketorolac administration, pharmaceutical confounder, dichotomized surgical procedure, and craniotomy for epilepsy and brain resection ( Table 6 ). Ketorolac was not associated with an elevated likelihood of radiographically identified bleeding controlling for these other factors (OR 0.81; 95% CI 0.43-1.51). In this case, the model fit was acceptable (c = 0.7).
discussion
NSAIDs can be very effective components of a multimodal postoperative analgesic regimen and have been shown to reduce postoperative opioid requirements. 5, 21 In our institution, perioperative ketorolac has been in routine use for nearly 15 years. To our knowledge, this study represents the largest assessment of perioperative bleeding events associated with ketorolac use in neurosurgery. Bivariable analysis was performed to identify factors that could confound the relationship between ketorolac use and hemorrhage. Multivariate analysis was performed to estimate the association between ketorolac use and radiographically identified postoperative hemorrhage, accounting for the factors identified by the bivariable analysis. This included pharmaceutical confounders, surgical procedure, and craniotomy for epilepsy and brain resection.
While the presence of a pharmacological confounder was associated with a higher rate of hemorrhage in bivariable analysis, the use of ketorolac in this context did not increase the risk for hemorrhage. Because of the small number of clinically significant postoperative hemorrhage events (n = 7), we were unable to perform multivariable analysis. Although there was no statistically significant bivariable association between ketorolac use and clinically significant postoperative hemorrhage (Table 7) , this finding should be confirmed in larger studies in which covariables such as pharmaceutical confounders and age could be evaluated. The c-statistic for the bivariable model (c = 0.5) suggests that other factors we were unable to consider might help explain this relationship. Because of a decidedly small number of events (n = 2 for each), we were unable to assess whether ketorolac was associated with an increased rate of renal failure or gastrointestinal tract injury.
Our findings indicate that the routine use of perioperative ketorolac in pediatric neurosurgery is not associated with an increased risk for bleeding events. Prior investigations of postoperative bleeding risk associated with NSAID use in neurosurgery have shown varying results. Bauer and colleagues 4 retrospectively analyzed 51 children who underwent craniotomy for resection of a brain tumor. Postoperatively, patients received ibuprofen alternating with acetaminophen every 4 to 6 hours. No patient suffered a symptomatic hemorrhage. Moderate hemorrhage was noted in a single patient (1.9%) and small, expected postoperative blood products were appreciated on 17.6% of postoperative imaging studies. In a population of adults undergoing elective craniotomy, Magni and colleagues 23 did not identify an association between perioperative ketorolac administration and postoperative intracranial hemorrhage requiring operative evacuation. Nonoperative hemorrhage was not evaluated in the study. In contrast to these studies, Palmer and colleagues 27 found that antiplatelet agents were among the principle risk factors for the development of postoperative hematoma requiring evacuation in their principally adult neurosurgery population. While this study included more than 6600 procedures, the perioperative use of aspirin was not distinguished from other NSAIDs, substantially limiting the value of this work in the assessment of ketorolac use.
In a randomized study evaluating the efficacy of a single dose of ketorolac versus morphine in the postoperative pediatric critical care setting, Lieh-Lai and colleagues reported no difference in bleeding time between the 2 groups and there were no cases of gastrointestinal hemorrhage. 22 Their study population of 102 children included 24 patients who underwent neurosurgical procedures. Cassinelli and colleagues 8 also reported no bleeding, renal, or hepatic complications in a randomized trial of ketorolac versus placebo for adults undergoing lumbar decompression. A recent meta-analysis of perioperative ketorolac use that examined 27 studies and 2314 patients demonstrated no significant increase in perioperative bleeding events and found ketorolac to be superior to opioids in controlling postoperative pain. 16 The findings of our study are consistent with these reports, indicating no relationship between short-term ketorolac treatment and postoperative hemorrhage. The most notable limitations to this study are the use of retrospective observational data and the small number of clinically significant bleeding events. Additionally, as the data come from a single institution, the study results may not be generalizable. This limitation may specifically apply to adult populations, as there are significant differences between the volume of distribution and plasma clearance of ketorolac between children and adults. 14 Selection bias may also affect our results. Specifically, a minority (37%) of patients received postoperative axial imaging and/or evaluation of renal function. These evaluations were completed primarily based on routine clinical practice but also in cases where concern regarding the patient's clinical status mandated a radiographic or laboratory evaluation. While these patients would have a greater likelihood of abnormal findings than the overall sample, there is no bias regarding the use of ketorolac in those who were evaluated. We prioritized the inclusion of procedures that we believed to be associated with the highest risk for hemorrhage. While we believed that procedures involving intradural placement of a catheter or endoscope (e.g., ventricular shunt or endoscopy) would be associated with more bleeding risk than extradural craniotomies/craniectomies (e.g., craniosynostosis repair or Chiari malformation decompression), the proportion of radiographic hemorrhage was higher in the latter group (10.5% vs 6%). If a substantial number of patients had a procedure in both of these categories and the intradural catheter/endoscope cases were preferentially included in the cohort, then ra- diographic hemorrhage may be underestimated. The use of ketorolac was also not evenly distributed among the different surgical groups. This resulted from our practice of discharging many patients who undergo shunt placement/ revision or endoscopy on postoperative Day 1. In preparation for this, many such patients are treated with an oral analgesic regimen including ibuprofen rather than receiving parenteral ketorolac. An additional limitation of this study is that our outcome assessment relied largely on the dictated report of the attending pediatric neuroradiologist. While all positive findings were confirmed in a blinded fashion and the radiology reports were generated prospectively and in an unbiased manner, there is likely to be variability in the language chosen for the neuroradiology report, which may have influenced our detection of clinically silent radiographic hemorrhage. Despite these limitations, we believe this study supports the notion that ketorolac is not associated with bleeding events or bleeding on imaging when used as part of a short-term perioperative pain management regimen following pediatric neurosurgery (Tables 6  and 7 ).
conclusions
We retrospectively reviewed a large, single-institution experience of perioperative (up to 72 hours) ketorolac use across the entire breadth of pediatric neurosurgical procedures. The results suggest no relationship between ketorolac use and radiographic or clinically significant bleeding events in the postoperative period. In combination with previous studies regarding the efficacy of ketorolac in decreasing narcotic usage, 1, 2, 5, 11, 14, 15, 20, 23 as well as the rationale for minimizing the use of sedating medications following neurosurgery, this study supports ketorolac as an option in the perioperative setting among the pediatric neurosurgical population. The role of perioperative ketorolac in pediatric neurosurgery should be further explored through larger prospective studies.
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